{"id":812394,"date":"2025-02-12T16:39:56","date_gmt":"2025-02-12T21:39:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/"},"modified":"2025-02-12T16:39:56","modified_gmt":"2025-02-12T21:39:56","slug":"portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/","title":{"rendered":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DOVER, Del., Feb.  12, 2025  (GLOBE NEWSWIRE) &#8212; Portage Biotech, Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) that Nasdaq has accepted Portage\u2019s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders\u2019 equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.<\/p>\n<p align=\"justify\">Nasdaq will periodically review Portage\u2019s adherence to the plan milestones. If Portage is not in compliance with the continued listing standards by June 9, 2025, or if Portage does not make progress consistent with the plan during the plan period, Nasdaq will initiate delisting proceedings as appropriate. At that time, the Company may appeal Nasdaq\u2019s determination to a Hearings Panel.<\/p>\n<p align=\"justify\">\n        <strong>About Portage Biotech, Inc.<br \/><\/strong>Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system\u2019s ability to fight cancer. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1BVVAIrDdVMZDbIKiIJqt2RLcH9KeW9Ha1woLAhFqG8CM9c8k018UJSq-1kQI-w0AW88cXCdUmUcm6pmkMQsiI-Nsz42U-kKwqDVvtlaq5I=\" rel=\"nofollow\" target=\"_blank\">www.portagebiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<br \/><\/strong>All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company\u2019s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words \u201cbelieve,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201ccontinues,\u201d or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company\u2019s ability to continue as a going concern, and other factors set forth in \u201cItem 3 &#8211; Key Information-Risk Factors\u201d in the Company\u2019s Annual Report on Form 20-F for the year ended March 31, 2024 and \u201cBusiness Environment \u2013 Risk Factors\u201d in the Company\u2019s Management\u2019s Discussion and Analysis for the Three and Six Months ended September 30, 2024 filed as Exhibit 99.2 to the Company\u2019s Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>For More Information:<\/strong><br \/>\n        <br \/>Portage Biotech<br \/>Alexander Pickett, Chief Executive Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XLn_i_mGaZi8mDAdt7K6ncqnI556xvJM994V_2ss7EKsefOat7ct9QOaepRR5ypcCkNV6LL_uxwZATrQMtKkDzEJp1in4VU0lVZRz3p9LH4=\" rel=\"nofollow\" target=\"_blank\">ir@portagebiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmZhYjcyOWYtZDQyOC00OGVlLTlhODItYmIyOGUyYTllNTk0LTEyMjEzMjI=\/tiny\/Portage-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech, Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) that Nasdaq has accepted Portage\u2019s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders\u2019 equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812394","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech, Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) that Nasdaq has accepted Portage\u2019s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders\u2019 equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income &hellip; Continue reading &quot;Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T21:39:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements\",\"datePublished\":\"2025-02-12T21:39:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/\"},\"wordCount\":490,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/\",\"name\":\"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\",\"datePublished\":\"2025-02-12T21:39:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk","og_description":"DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech, Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) that Nasdaq has accepted Portage\u2019s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the \u201cCapital Market\u201d) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders\u2019 equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income &hellip; Continue reading \"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-12T21:39:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements","datePublished":"2025-02-12T21:39:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/"},"wordCount":490,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/","name":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=","datePublished":"2025-02-12T21:39:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzUxNiM2NzQ4NTU1IzIyMDk3Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-receives-extension-of-time-to-attain-compliance-with-stock-exchange-continued-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812394"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812394\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}